Squarepoint
LRMR icon

Squarepoint’s Larimar Therapeutics LRMR Stock Holding History

Squarepoint’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$346K Buy
+113,474
New +$451K ﹤0.01% 3701
2026
Q1 		– Sell
-30,416
Closed -$116K – 4669
2025
Q4 		$116K Buy
+30,416
New +$118K ﹤0.01% 4013
2025
Q1 		– Sell
-28,071
Closed -$109K – 5072
2024
Q4 		$109K Sell
28,071
-14,724
-34% -$97.2K ﹤0.01% 4680
2024
Q3 		$280K Buy
42,795
+12,937
+43% +$104K ﹤0.01% 3497
2024
Q2 		$216K Buy
+29,858
New +$229K ﹤0.01% 3619
2023
Q2 		– Sell
-30,655
Closed -$139K – 3819
2023
Q1 		$139K Buy
+30,655
New +$160K ﹤0.01% 2904
2020
Q2 		– Sell
-865
Closed -$8K – 2392
2020
Q1 		$8K Sell
865
-2,137
-71% -$28.1K ﹤0.01% 1784
2019
Q4 		$40K Buy
+3,002
New +$28.7K ﹤0.01% 2406
2019
Q2 		– Sell
-1,542
Closed -$51K – 2548
2019
Q1 		$51K Sell
1,542
-5,321
-78% -$273K ﹤0.01% 2080
2018
Q4 		$408K Buy
6,863
+2,938
+75% +$290K ﹤0.01% 1360
2018
Q3 		$551K Buy
3,925
+2,867
+271% +$348K 0.01% 1255
2018
Q2 		$130K Buy
+1,058
New +$89.9K ﹤0.01% 1617
2018
Q1 		– Sell
-1,575
Closed -$87K – 1941
2017
Q4 		$87K Sell
1,575
-2,292
-59% -$103K ﹤0.01% 1974
2017
Q3 		$163K Buy
3,867
+2,870
+288% +$119K ﹤0.01% 1439
2017
Q2 		$42K Buy
+997
New +$51K ﹤0.01% 1466
2017
Q1 		– Sell
-904
Closed -$35K – 1739
2016
Q4 		$35K Buy
+904
New +$36.7K ﹤0.01% 1711
2016
Q2 		– Sell
-5,708
Closed -$458K – 1244
2016
Q1 		$458K Buy
5,708
+4,241
+289% +$335K 0.04% 659
2015
Q4 		$111K Buy
+1,467
New +$236K 0.01% 1122

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Squarepoint's LRMR Position: Q2 2026 in Review

Squarepoint opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 113,474 shares worth $346K. The stake represents ﹤0.01% of the portfolio and ranks #3701 among its holdings. This is a return to the name: Squarepoint previously reported a position in LRMR as recently as Q4 2025.

Squarepoint first reported a position in LRMR in Q4 2015 and has held it in 18 quarters since. The position peaked at $551K in Q3 2018. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Squarepoint held 113,474 shares of Larimar Therapeutics worth $346K as of Q2 2026.
  • Larimar Therapeutics was a new Squarepoint position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3701 holding.
  • Squarepoint first reported a position in Larimar Therapeutics in Q4 2015 and has held it in 18 quarters since.
  • Squarepoint's Larimar Therapeutics position peaked at $551K in Q3 2018.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.